PIK3CA and pancreatic adenocarcinoma: In one further study, patients with advanced cancers who were referred to a phase I program for targeted therapy, were analyzed for PIK3CA status.36 Of 217 patients, 25 were found to have PIK3CA mutations, of which 1 had pancreatic adenocarcinoma.